Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients

This study has been terminated.
(IND voluntarily withdrawn, without prejudice)
Sponsor:
Information provided by (Responsible Party):
Amphastar Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00635505
First received: March 7, 2008
Last updated: July 11, 2013
Last verified: July 2012
  Purpose

This 12-week clinical study evaluates the safety and efficacy of Albuterol Sulfate HFA Inhalation Aerosol (Albuterol-HFA, or: A004), Armstrong's proposed HFA formulation of metered dose inhaler (MDI) of Albuterol (Treatment T), in comparison with:

  1. Placebo control: (HFA propellant only, Treatment P); and
  2. Active control: 3M/Key's Proventil-HFA (Treatment R).

The treatments will be given as self-administered oral inhalations in adult and adolescent patients with mild-to-moderate asthma, for 12-weeks. Dosing regimen throughout the 12-week study is two actuations four times daily (QID).


Condition Intervention Phase
Asthma
Drug: albuterol HFA (Armstrong's)
Drug: albuterol HFA (Proventil HFA)
Drug: HFA placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Placebo-Controlled, Parallel, Multi-Center, 12-Week Study to Evaluate the Efficacy and Safety of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Adult and Adolescent Asthmatic Patients

Resource links provided by NLM:


Further study details as provided by Amphastar Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • The primary endpoint is the bronchodilator effect expressed as the mean area under the curve (AUC) of FEV1 (% change from Same-Day Baseline FEV1) versus time. [ Time Frame: Concurent with each visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The comparative analysis of AUC of FEV1 (% change from the Same-Day Baseline) versus time, for bronchodilator effect (between Albuterol-HFA and Proventil-HFA). [ Time Frame: End of Study ] [ Designated as safety issue: No ]
  • AUC of FEV1-time curve (changes of actual volumes from the Same-Day Baseline). [ Time Frame: End of Study ] [ Designated as safety issue: No ]
  • Time to onset of bronchodilator effect, determined by linear interpolation as the time point where FEV1 first reaches 12% over Same-Day Baseline. [ Time Frame: End of Study ] [ Designated as safety issue: No ]
  • The peak bronchodilator response, defined as the maximum FEV1 (% change from Same-Day Baseline) post-dose. [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • The time to peak FEV1 effect, measured as the time point of peak response, as defined (4) above. [ Time Frame: End of Study ] [ Designated as safety issue: No ]
  • Duration of bronchodilator effect, defined as the total length of time when FEV1 is maintained 12% above the respective Same-Day Baseline values (time points calculated with linear interpolation). [ Time Frame: Concurrent with each visit ] [ Designated as safety issue: No ]
  • Percentage of positive responders including those whose FEV1 exceed the Same-Day Baseline by 12% within 30 minutes post-dose (quick responders), and during the entire 6 hr post-dose (overall responders). [ Time Frame: Concurrent with visit ] [ Designated as safety issue: No ]
  • Number of inhalations of the rescue inhalers taken. [ Time Frame: Concurrent with each visit ] [ Designated as safety issue: No ]
  • Global assessment of Overall Asthma Control Scores by investigators. [ Time Frame: End of Study ] [ Designated as safety issue: No ]
  • Total daytime asthma symptom scores. [ Time Frame: End of Study ] [ Designated as safety issue: No ]
  • Nighttime sleep disturbance scores. [ Time Frame: End of Study ] [ Designated as safety issue: No ]
  • Morning pre-dose Peak Expiratory Flow Rate (PEF). [ Time Frame: Concurrent with each visit ] [ Designated as safety issue: No ]
  • The clinical performances of the Albuterol-HFA MDI at the representative first, middle and last one third of the usable life stage, are compared with each other, and are also compared to those of the active control, Proventil-HFA. [ Time Frame: End of Study ] [ Designated as safety issue: No ]
  • The in vitro performance of the Albuterol-HFA MDI will be evaluated. [ Time Frame: Concurrent with each visit ] [ Designated as safety issue: No ]
  • Vital signs (SBP/DBP, and heart rate) will be monitored at Clinical Visit 1, 3 and 5, at baseline (within 30 minutes prior to dosing), and 90+/-15 min, and 360+/-30 min, post-dose. [ Time Frame: concurrent with study visits as noted ] [ Designated as safety issue: Yes ]
  • A 12-lead ECG (for HR, QT and QTc intervals) will be recorded at Screening Visit, and at baseline (within 30 min) pre-dose and at 90+/-15 min post-dose (predicted time of peak effect). [ Time Frame: Clinical Visits 1 and 5 ] [ Designated as safety issue: Yes ]
  • Data for CBC, blood chemistry panel (8-hr fasted), and urinalysis. [ Time Frame: Screening and end-of-study ] [ Designated as safety issue: Yes ]
  • Study compliance and diaries will be reviewed [ Time Frame: at all cliniical visits ] [ Designated as safety issue: Yes ]
  • Concomitant medications will be reviewed and recorded [ Time Frame: each study visit ] [ Designated as safety issue: Yes ]
  • Adverse events/side effects whether observed by investigators or reported by subjects, will be documented, evaluated, followed up, and treated if deemed necessary. [ Time Frame: concurrent with each study visit ] [ Designated as safety issue: Yes ]

Enrollment: 300
Study Start Date: September 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: T
albuterol HFA 180 mcg QID
Drug: albuterol HFA (Armstrong's)
180 mcg QID 12 weeks
Active Comparator: R
180 mcg QID 12 weeks
Drug: albuterol HFA (Proventil HFA)
180 mcg QID 12 weeks
Other Name: Proventil HFA
Placebo Comparator: P
2 actuations QID 12 weeks or until use of rescue drug
Drug: HFA placebo
2 actuations QID 12 weeks or until use of rescue drug

Detailed Description:

This is a randomized, parallel, multicenter, 12-week study in adolescent and adult patients with mild-to-moderate asthma, to evaluate the efficacy and safety of Armstrong's Albuterol-HFA MDI, in comparison to a Placebo Control and an Active Control of Proventil-HFA. While Albuterol-HFA (Treatment T) and Placebo (Treatment P) will be double-blinded to both the subjects and investigational staff, the active comparator drug, Proventil-HFA (Treatment R), can only be evaluator-blinded, due to: (1) its physical appearance differing from that of the T and P devices; and (2) unavailability of a Proventil-HFA placebo which would otherwise be used for a double-dummy design. All study medications will have the canisters and all product-identifying text or graphics (e.g., molded text on actuator) masked so that the treatments cannot be identified. No subject in any study arm will be given any information that could reveal the nature of the treatment given. All study subjects will be instructed not to reveal or discuss the study medications to the study staff or other subjects. The designated study evaluator(s), who conduct the clinical visits and safety and efficacy evaluations and perform the data recording and transcription, will be blinded to the study medications.

All subjects will be screened for enrollment, and will be randomized into the following three treatment groups in a double-blinded (for Treatments T and P) or evaluator-blinded (for Treatment R) manner:

Treatment T (Albuterol-HFA, N=200): 216 mcg albuterol sulfate (equivalent to 180 mcg albuterol base), QID; Treatment R (Proventil-HFA, N=50): 216 mcg albuterol sulfate (equivalent to 180 mcg albuterol base), QID; Treatment P (Placebo-HFA, N=50): two actuations of placebo, QID.

Randomization is achieved with blocks of six (6), with four (4) patients receiving Albuterol-HFA for every one (1) patient receiving Proventil-HFA and every one (1) receiving the Placebo-HFA. At each Clinical Visit that takes place every 3 weeks, the double-blinded (T, P) or evaluator-blinded (R) study drugs will be distributed in resealable masking pouches to the subjects of each arm.

An additional aim of the study is to evaluate the effect of weekly cleaning on the Albuterol-HFA MDI device clinical performance throughout the four, 3-week life-of-device treatment cycles, in conformance with the FDA's specific requirements.

Arms:

All subjects will be screened for enrollment, and will be randomized into the following three treatment groups in a double-blinded (for Treatments T and P) or evaluator-blinded (for Treatment R) manner:

Treatment T (Albuterol-HFA, N=200): 216 mcg albuterol sulfate (equivalent to 180 mcg albuterol base), QID; Treatment R (Proventil-HFA, N=50): 216 mcg albuterol sulfate (equivalent to 180 mcg albuterol base), QID; Treatment P (Placebo-HFA, N=50): two actuations of placebo, QID.

  Eligibility

Ages Eligible for Study:   12 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female asthma patients aged 12 - 75 years, in general good health.
  • A documented history of mild to moderate asthma, for at-least 6-months prior to Screening, requiring inhaled B2-adrenergic agonists, with or without orally inhaled corticosteroids, for asthma treatment.
  • Satisfying criteria of asthma stability, defined as no asthma-related hospitalization or emergency visits, and no significant changes in asthma therapy, over 4 weeks prior to Screening (with exception for switching from long- to short-acting B2-agonists).
  • Can tolerate withholding treatment with inhaled bronchodilators and other allowed medications for the minimum washout periods indicated in Appendix II prior to the Screening Baseline FEV1 testing.
  • Having a Screening Baseline FEV1 test that falls within 50-90% of the predicted values.
  • Airway Reversibility PFT at screening should demonstrate a greater than 12% increase in FEV1 at 30 minutes of inhaling 2 actuations of Ventolin-HFA (180 mcg albuterol base).
  • Demonstrating satisfactory techniques in the use of metered-dose inhaler (MDIs) and a hand held peak flow meter.
  • Female patients of child-bearing potential being non-pregnant and non-lactating at Screening and throughout the study, and using an acceptable method of contraception during the study.
  • Has properly consented to participate in this study.

Exclusion Criteria:

  • Male and female asthma patients aged 12 - 75 years, in general good health.
  • A documented history of mild to moderate asthma, for at-least 6-months prior to Screening, requiring inhaled B2-adrenergic agonists, with or without orally inhaled corticosteroids, for asthma treatment.
  • Satisfying criteria of asthma stability, defined as no asthma-related hospitalization or emergency visits, and no significant changes in asthma therapy, over 4 weeks prior to Screening (with exception for switching from long- to short-acting B2-agonists).
  • Can tolerate withholding treatment with inhaled bronchodilators and other allowed medications for the minimum washout periods indicated in Appendix II prior to the Screening Baseline FEV1 testing.
  • Having a Screening Baseline FEV1 test that falls within 50-90% of the predicted values.
  • Airway Reversibility PFT at screening should demonstrate a greater than12% increase in FEV1 at 30 minutes of inhaling 2 actuations of Ventolin-HFA (180 mcg albuterol base).
  • Demonstrating satisfactory techniques in the use of metered-dose inhaler (MDIs) and a hand held peak flow meter.
  • Female patients of child-bearing potential being non-pregnant and non-lactating at Screening and throughout the study, and using an acceptable method of contraception during the study.
  • Has properly consented to participate in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00635505

  Show 42 Study Locations
Sponsors and Collaborators
Amphastar Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Amphastar Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00635505     History of Changes
Other Study ID Numbers: API-A004-CLN-C
Study First Received: March 7, 2008
Last Updated: July 11, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Amphastar Pharmaceuticals, Inc.:
Asthma
albuterol
HFA

Additional relevant MeSH terms:
Asthma
Anti-Asthmatic Agents
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Albuterol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Respiratory System Agents
Therapeutic Uses
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014